A share price of UroGen Pharma Ltd [URGN] is currently trading at $12.03, up 8.57%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The URGN shares have gain 63.23% over the last week, with a monthly amount glided 21.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on May 22, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Scotiabank started tracking the stock with Sector Outperform rating on April 16, 2025, and set its price target to $23. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $40 on August 22, 2024. Jefferies downgraded its rating to a Hold and reduced its price target to $10 on February 08, 2023. Berenberg started tracking with a Buy rating for this stock on April 27, 2022, and assigned it a price target of $20. In a note dated April 16, 2020, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $53 to $57.
UroGen Pharma Ltd experienced fluctuations in its stock price throughout the past year between $3.42 and $20.70. Currently, Wall Street analysts expect the stock to reach $38.6 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $12.03 at the most recent close of the market. An investor can expect a potential return of 220.86% based on the average URGN price forecast.
Analyzing the URGN fundamentals
Trailing Twelve Months sales for UroGen Pharma Ltd [NASDAQ:URGN] were 91.87M which represents 7.84% growth. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.18%, Pretax Profit Margin comes in at -1.47%, and Net Profit Margin reading is -1.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -974.87 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.93 points at the first support level, and at 9.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.71, and for the 2nd resistance point, it is at 15.39.
Ratios To Look Out For
To put it in perspective, the Current Ratio for UroGen Pharma Ltd [NASDAQ:URGN] is 5.65. As well, the Quick Ratio is 5.47, while the Cash Ratio is 2.48. Considering the valuation of this stock, the price to sales ratio is 6.04.
Transactions by insiders
Recent insider trading involved Schoenberg Mark, Chief Medical Officer, that happened on Jun 09 ’25 when 5162.0 shares were sold. Officer, Schoenberg Mark completed a deal on Jun 09 ’25 to buy 5162.0 shares. Meanwhile, Chief Medical Officer Schoenberg Mark sold 4551.0 shares on Jan 31 ’25.
